Free Trial

Aura Biosciences (AURA) Competitors

Aura Biosciences logo
$6.55 +0.08 (+1.24%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$6.55 0.00 (0.00%)
As of 08/22/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AURA vs. ETNB, EWTX, WVE, ABCL, HROW, VERA, ARDX, COGT, AVDL, and CVAC

Should you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include 89BIO (ETNB), Edgewise Therapeutics (EWTX), WAVE Life Sciences (WVE), AbCellera Biologics (ABCL), Harrow (HROW), Vera Therapeutics (VERA), Ardelyx (ARDX), Cogent Biosciences (COGT), Avadel Pharmaceuticals (AVDL), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

Aura Biosciences vs. Its Competitors

Aura Biosciences (NASDAQ:AURA) and 89BIO (NASDAQ:ETNB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Aura Biosciences had 6 more articles in the media than 89BIO. MarketBeat recorded 11 mentions for Aura Biosciences and 5 mentions for 89BIO. 89BIO's average media sentiment score of 0.98 beat Aura Biosciences' score of 0.62 indicating that 89BIO is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aura Biosciences
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
89BIO
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aura Biosciences' return on equity of -64.44% beat 89BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Aura BiosciencesN/A -64.44% -54.24%
89BIO N/A -94.48%-80.92%

96.8% of Aura Biosciences shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 2.6% of 89BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aura Biosciences presently has a consensus price target of $22.00, indicating a potential upside of 235.88%. 89BIO has a consensus price target of $26.29, indicating a potential upside of 178.75%. Given Aura Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aura Biosciences is more favorable than 89BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aura Biosciences
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.11
89BIO
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

Aura Biosciences is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aura BiosciencesN/AN/A-$86.92M-$1.96-3.34
89BION/AN/A-$367.08M-$3.61-2.61

Aura Biosciences has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, 89BIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Summary

Aura Biosciences beats 89BIO on 10 of the 13 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AURA vs. The Competition

MetricAura BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$406.89M$3.11B$5.81B$9.76B
Dividend YieldN/A2.23%4.39%4.06%
P/E Ratio-3.3421.0031.3626.05
Price / SalesN/A209.44387.8788.42
Price / CashN/A44.5038.0259.36
Price / Book2.338.129.536.60
Net Income-$86.92M-$54.72M$3.26B$265.65M
7 Day Performance-2.53%2.62%2.14%2.00%
1 Month Performance-7.22%3.25%3.22%0.46%
1 Year Performance-13.70%10.82%30.19%18.88%

Aura Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AURA
Aura Biosciences
1.8351 of 5 stars
$6.55
+1.2%
$22.00
+235.9%
-13.7%$406.89MN/A-3.3450Analyst Upgrade
ETNB
89BIO
2.0115 of 5 stars
$8.77
-4.3%
$26.29
+199.7%
+6.5%$1.34BN/A-2.4340
EWTX
Edgewise Therapeutics
2.3903 of 5 stars
$12.99
+2.4%
$41.60
+220.2%
-23.2%$1.34BN/A-8.3860News Coverage
Analyst Forecast
WVE
WAVE Life Sciences
4.7597 of 5 stars
$8.10
+0.1%
$20.27
+150.2%
+76.8%$1.29B$108.30M-9.00240Positive News
ABCL
AbCellera Biologics
2.0891 of 5 stars
$4.50
+5.9%
$8.00
+77.8%
+68.2%$1.27B$28.83M-8.18500
HROW
Harrow
3.6201 of 5 stars
$33.74
-2.0%
$63.83
+89.2%
-8.4%$1.26B$199.61M-60.25180Analyst Revision
High Trading Volume
VERA
Vera Therapeutics
3.7276 of 5 stars
$20.17
+1.9%
$63.00
+212.3%
-42.6%$1.26BN/A-5.6340News Coverage
Positive News
ARDX
Ardelyx
4.3096 of 5 stars
$5.40
+3.6%
$11.50
+113.0%
-3.8%$1.26B$333.61M-23.4890Positive News
COGT
Cogent Biosciences
3.6095 of 5 stars
$10.93
-0.3%
$18.70
+71.1%
+19.1%$1.25BN/A-6.1480Positive News
AVDL
Avadel Pharmaceuticals
2.7 of 5 stars
$12.79
+0.3%
$18.67
+45.9%
-7.6%$1.23B$169.12M-426.3370Analyst Forecast
CVAC
CureVac
4.6395 of 5 stars
$5.43
-0.2%
$6.83
+25.8%
+64.4%$1.22B$579.18M5.90880News Coverage
Earnings Report
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:AURA) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners